Full Length Research Paper
References
|
Berger I, Haubrich K, Ensom MHH, Carr R. RELATE (2019).: Relationship of limited sampling strategy and adverse effects of mycophenolate mofetil in pediatric renal transplant patients. Pediatr Transplant. Mars 23(2):e13355. |
|
|
Brandhorst G, Marquet P, Shaw LM, Liebisch G, Schmitz G, Coffing MJ (2008). Multicenter evaluation of a new inosine monophosphate dehydrogenase inhibition assay for quantification of total mycophenolic acid in plasma. Therapeutic Drug Monitoring. Août 30(4):428 433. |
|
|
Cai W, Ye C, Sun X, Qin K, Qin Y, Zhao D (2015). Limited sampling strategy for predicting area under the concentration-time curve for mycophenolic Acid in Chinese adults receiving mycophenolate mofetil and tacrolimus early after renal transplantation. Therapeutic Drug Monitoring 37(3):304 310. |
|
|
David-Neto E, Pereira Araujo LM, Sumita NM, Mendes ME, Ribeiro Castro MC, Alves CF (2003). Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. Pediatr Nephrol Berl Ger. Mars 18(3):266 272. |
|
|
de Winter BCM, Mathot RAA, Sombogaard F, Vulto AG, van Gelder T (2011). Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. Clinical Journal of the American Society of Nephrology CJASN. Mars 6(3):656 663. |
|
|
de Winter BCM, Mathot RAA, Sombogaard F, Vulto AG, van Gelder T (2011). Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. Clinical Journal of the American Society of Nephrology CJASN. Mars 6(3):656 663. |
|
|
Ehren R, Schijvens AM, Hackl A, Schreuder MF, Weber LT (2021). Therapeutic drug monitoring of mycophenolate mofetil in pediatric patients: novel techniques and current opinion. Expert Opinion on Drug Metabolism and Toxicology 17(2):201 213. |
|
|
Filler G, Alvarez-Elías AC, McIntyre C, Medeiros M (2017). The compelling case for therapeutic drug monitoring of mycophenolate mofetil therapy. Pediatric Nephrology Berl Ger. 32(1):21 29. |
|
|
Fukuda T, Goebel J, Thøgersen H, Maseck D, Cox S, Logan B (2011). Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. Journal of Clinical Pharmacology 51(3):309 320. |
|
|
Giavarina D (2015). Understanding Bland Altman analysis. Biochemia Medica. 25(2):141 151. |
|
|
Höcker B, van Gelder T, Martin-Govantes J, Machado P, Tedesco H, Rubik J (2011). Comparison of MMF efficacy and safety in paediatric vs. adult renal transplantation: subgroup analysis of the randomised, multicentre FDCC trial. Nephrol Dial Transplant Off Publ Eur Dial Transplant Association-European Renal Association 26(3):1073 1079. |
|
|
Kant S, Kronbichler A, Geetha D (2022). Principles of Immunosuppression in the Management of Kidney Disease: Core Curriculum 2022. American Journal of Kidney Diseases 80(3):393 405. |
|
|
Lancia P, Jacqz-Aigrain E, Zhao W (2014). Choosing the right dose of tacrolimus. Archives of Disease in Childhood 21 p. |
|
|
Le Meur Y, Borrows R, Pescovitz MD, Budde K, Grinyo J, Bloom R (2011). Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting. Transplant Review Orlando Fla. 25(2):58 64. |
|
|
Le Meur Y, Büchler M, Thierry A, Caillard S, Villemain F, Lavaud S, Marquet P (2007). Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. American Journal of Transplantation 7(11):2496-2503. |
|
|
Resztak M, Sobiak J, Czyrski A (2021). Recent advances in therapeutic drug monitoring of voriconazole, mycophenolic acid, and vancomycin: a literature review of pediatric studies. Pharmaceutics 13(12):1991. https://pubmed.ncbi.nlm.nih.gov/34959272/ |
|
|
Pan H, Gazarian A, Fourier A, Gagnieu MC, Leveneur O, Sobh M (2014). Short-term pharmacokinetic study of mycophenolate mofetil in neonatal swine. Transplantation Proceedings 46(10):3620 3628. |
|
|
Pawinski T, Luszczynska P, Durlik M, Majchrzak J, Baczkowska T, Chrzanowska M (2013).. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus. Therapeutic Drug Monitoring 35(6):760 769. |
|
|
Radzevi?ien? A, Stankevi?ius E, Saint-Marcoux F, Marquet P, Maslauskienë R, Kaduševi?ius E (2020). Pharmacokinetic evaluation of MFF in combinations with tacrolimus and cyclosporine. Findings of C0 and AUC. Medicine (Baltimore). 99(12):e19441. |
|
|
Sánchez Fructuoso AI, Perez-Flores I, Calvo N, Valero R, Matilla E, Ortega D (2012). Limited-sampling strategy for mycophenolic acid in renal transplant recipients reciving enteric-coated mycophenolate sodium and tacrolimus. Therapeutic Drug Monitoring 34(3):298 305. |
|
|
Smits TA, Cox S, Fukuda T, Sherbotie JR, Ward RM, Goebel J (2014). Effects of unbound mycophenolic acid on inosine monophosphate dehydrogenase inhibition in pediatric kidney transplant patients. Therapeutic Drug Monitoring 36(6):716 723. |
|
|
Sobiak J, ?ero P, Zachwieja J, Ostalska-Nowicka D, Pawi?ski T (2023). Limited sampling strategy to predict free mycophenolic acid area under the concentration-time curve in paediatric patients with nephrotic syndrome. Clinical and Experimental Pharmacology and Physiology 50(6):486 496. |
|
|
Tett SE, Saint-Marcoux F, Staatz CE, Brunet M, Vinks AA, Miura M (2011). Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplant Rev Orlando Fla. 25(2):47 57. |
|
|
van der Meer AF, Marcus MAE, Touw DJ, Proost JH, Neef C (2011). Optimal sampling strategy development methodology using maximum a posteriori Bayesian estimation. Therapeutic Drug Monitoring 33(2):133 146. |
|
|
Weber LT, Hoecker B, Armstrong VW, Oellerich M, Tönshoff B (2006). Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients. Therapeutic Drug Monitoring 28(5):623 631. |
|
|
Woillard JB, Picard N, Thierry A, Touchard G, Marquet P (2014). DOMINOS study group. Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients. Pharmacogenetics and Genomics 24(5):256-262. |
|
|
Xiang H, Zhou H, Zhang J, Sun Y, Wang Y, Han Y, Cai J (2021). Limited sampling strategy for estimation of mycophenolic acid exposure in adult Chinese heart transplant recipients. Frontiers in Pharmacology 12:652333. |
|
|
Yamaguchi K, Fukuoka N, Kimura S, Watanabe M, Tani K, Tanaka H (2013). Limited sampling strategy for the estimation of mycophenolic acid area under the concentration-time curve treated in Japanese living-related renal transplant recipients with concomitant extended-release tacrolimus. Biological and Pharmaceutical Bulletin 36(6):1036 1039. |
|
|
Zhang J, Sun Z, Zhu Z, Yang J, Kang J, Feng G (2018). Pharmacokinetics of Mycophenolate Mofetil and Development of Limited Sampling Strategy in Early Kidney Transplant Recipients. Frontiers in Pharmacology 9:908. |
|
|
Zhao W, Fakhoury M, Jacqz-Aigrain E (2010). Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation. Therapeutic Drug Monitoring 32(6):688 699. |
|
Copyright © 2025 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
